Update on erythropoiesis-stimulating agents

Best Practice and Research: Clinical Anaesthesiology

Volumn 27, Issue 1, 2013, Pages 121-129

  Goodnough, Lawrence Tim ^a   Shander, Aryeh ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

anaemia; blood transfusion; erythropoietin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FOLIC ACID; HEMOGLOBIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTICOAGULANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOMA; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REIMBURSEMENT; REVIEW; RISK MANAGEMENT; SURGICAL PATIENT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION;

EID: 84876241684     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2012.11.006     Document Type: Review

References (85)

1. J.W. Eschbach, J.C. Egrie, and M.R. Downing Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial N Engl J Med 316 1987 73 78
2. J.W. Eschbach, M.H. Abdulhadi, and J.K. Browne Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial Ann Intern Med 111 1989 992 1000
3. A. Shander, M.D. Cappellini, and L.T. Goodnough Iron overload and toxicity: the hidden risk of multiple blood transfusions Vox Sang 97 2009 185 197
4. J.W. Eschbach, and J.W. Adamson Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy Kidney Int Suppl 69 1999 S35 S43
5. R.L. Pisoni, J.L. Bragg-Gresham, and E.W. Young Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 44 2004 94 111
6. L.T. Goodnough, T.G. Monk, and G.L. Andriole Erythropoietin therapy N Engl J Med 336 1997 933 938
7. A. Laupacis, and D. Fergusson Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators Transfus Med 8 1998 309 317
8. J. Glaspy, R. Bukowski, and D. Steinberg Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 15 1997 1218 1234
9. J. Vansteenkiste, R. Pirker, and B. Massuti Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
10. J. Seidenfeld, M. Piper, and C. Flamm Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 2001 1204 1214
11. J. Bohlius, J. Wilson, and J. Seidenfeld Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 2006 708 714
12. L.T. Goodnough, and A.S. Shander Current status of pharmacologic therapies in patient blood management Anesth Analg 116 2013 15 34 Epub 12/7/12
13. C.P. Stowell, S.C. Jones, and C. Enny An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis Spine 34 2009 2479 2485
14. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
15. A.K. Singh, L. Szczech, and K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
16. T.B. Drueke, F. Locatelli, and N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
17. M.A. Pfeffer, E.A. Burdmann, and C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
18. S.D. Solomon, H. Uno, and E.F. Lewis Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
19. E.F. Lewis, M.A. Pfeffer, and A. Feng Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial Clin J Am Soc Nephrol 6 2011 845 855
20. M. Hedenus, M. Adriansson, and J. San Miguel Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study Br J Haematol 122 2003 394 403
21. B. Leyland-Jones, V. Semiglazov, and M. Pawlicki Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J Clin Oncol 23 2005 5960 5972
22. M. Untch, P.A. Fasching, and G.E. Konecny PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer-results at the time of surgery Ann Oncol 22 2011 1988 1998
23. J. Overgaard, C. Hoff, and H. San Hansen Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 Eur J Cancer 7 Suppl. 5 2007 Abstract 6LB
24. G. Thomas, S. Ali, and F.J. Hoebers Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer Gynecol Oncol 108 2008 317 325
25. J.R. Wright, Y.C. Ung, and J.A. Julian Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J Clin Oncol 25 2007 1027 1032
26. R.E. Smith Jr., M.S. Aapro, and H. Ludwig Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study J Clin Oncol 26 2008 1040 1050
27. J. Glaspy, J. Crawford, and J. Vansteenkiste Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes Br J Cancer 102 2010 301 315
28. S.L. Seliger, A.D. Zhang, and M.R. Weir Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease Kidney Int 80 2011 288 294
29. S.D. Ross, I.E. Allen, and D.H. Henry Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature Clin Ther 28 2006 801 831
30. J. Seidenfeld, M. Piper, and J. Bohlius Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment Comparative effectiveness review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation center Evidence-based Practice Center under Contract No. 290-02-0026.) May 2006 Agency for Healthcare Research and Quality Rockville, MD Available at: www.effectivehealthcare.ahrq.gov/ reports/final.cfm
31. C.L. Bennett, S.M. Silver, and B. Djulbegovic Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 299 2008 914 924
32. J. Bohlius, K. Schmidlin, and C. Brillant Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
33. M. Henke, R. Laszig, and C. Rube Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
34. M. Tonelli, B. Hemmelgarn, and T. Reiman Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis CMAJ 180 2009 E62 E71
35. H. Ludwig, J. Crawford, and A. Osterborg Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia J Clin Oncol 27 2009 2838 2847
36. B.K. Hadland, and G.D. Longmore Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms J Clin Oncol 27 2009 4217 4226
37. M. Henke, D. Mattern, and M. Pepe Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24 2006 4708 4713
38. S. Elliott, L. Busse, and M.B. Bass Anti-Epo receptor antibodies do not predict Epo receptor expression Blood 107 2006 1892 1895
39. S. Elliott, L. Busse, and I. McCaffery Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells J Immunol Methods 352 2010 126 139
40. C.P. Miller, K.A. Lowe, and K. Valliant-Saunders Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial Stem Cells 27 2009 2353 2361
41. S. Swift, A.R. Ellison, and P. Kassner Absence of functional EpoR expression in human tumor cell lines Blood 115 2010 4254 4263
42. A.M. Sinclair, A. Coxon, and I. McCaffery Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells Blood 115 2010 4264 4272
43. E.S. Xenos, H.D. Vargas, and D.L. Davenport Association of blood transfusion and venous thromboembolism after colorectal cancer resection Thromb Res 129 2012 568 572
44. W.H. Geerts, K.I. Code, and R.M. Jay A prospective study of venous thromboembolism after major trauma N Engl J Med 331 1994 1601 1606
45. J.D. Rizzo, M. Brouwers, and P. Hurley American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer Blood 116 2010 4045 4059
46. Centers for Medicare and Medicaid Services. Decision memo for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications (CAG-00383N). Issue date: July 30, 2007. Last modified: January 14, 2010. Available at: https://www.cms.gov/mcd/viewdecisionmemo.asp?id=203 [accessed 21.08.12].
47. NCI cancer bulletin. http://www.cancer.gov/ncicancerbulletin/NCI-Cancer- Bulletin-051507/page2 [accessed 21.08.12].
48. FDA press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2008/ucm116830.htm [accessed 21.08.12].
49. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 2003 459 460
50. KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney Int Suppl 2 2012 311 316
51. E.F. Unger, A.M. Thompson, and M.J. Blank Erythropoiesis-stimulating agents-time for a reevaluation N Engl J Med 362 2010 189 192
52. United States Department of Health and Human Services The 2007 national blood collection and utilization report http://www.aabb.org/programs/ biovigilance/nbcus/Pages/default.aspx 2010
53. K. Larholt, T.M. Burton, and D.C. Hoaglin Clinical and patient-reported outcomes based on achieved hemoglobin levels in chemotherapy-treated cancer patients receiving erythropoiesis-stimulating agents Commun Oncol 6 2009 403 408
54. D.H. Henry, B.J. Brooks Jr., and D.C. Case Jr. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy Cancer J Sci Am 1 1995 252 260
55. D.L. Hershman, D.L. Buono, and J. Malin Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer J Natl Cancer Inst 101 2009 1633 1641
56. G. Hess, R.J. Nordyke, and J. Hill Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions Am J Hematol 85 2010 838 843
57. S. Vadhan-Raj, X. Zhou, and K. Sizer Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions Oncologist 15 2010 1359 1369
58. D.H. Henry, C.J. Langer, and R.S. McKenzie Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review Support Care Cancer 20 2012 2089 2096
59. B.A. Feinberg, A.S. Bruno, and S. Haislip Hemoglobin trends and anemia treatment resulting from concomitant chemotherapy in community oncology clinics J Oncol Pract 8 2012 18 23
60. T.J. Arneson, S. Li, and D.T. Gilbertson Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis- stimulating agent and transfusion use in chemotherapy-treated cancer patients Pharmacoepidemiol Drug Saf 21 2012 857 864
61. A.M. Audet, and L.T. Goodnough American College of Physicians position paper: strategies for elective red blood cell transfusion Ann Int Med 116 1992 403 406
62. G. Innes Guidelines for red blood cells and plasma transfusion for adults and children: an emergency physician's overview of the 1997 Canadian blood transfusion guidelines. Part 1: red blood cell transfusion. Canadian Medical Association Expert Working Group J Emerg Med 16 1998 129 131
63. L.J. Estcourt, S.J. Stanworth, and M.F. Murphy Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 154 2011 425 440
64. T.L. Simon, D.C. Alverson, and J. AuBuchon Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists Arch Pathol Lab Med 122 1998 130 138
65. L.T. Goodnough, and A.S. Shander Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine Am J Hematol 85 2010 835 837
66. L.T. Goodnough, M.E. Brecher, and M.H. Kanter Transfusion medicine. First of two parts-blood transfusion N Engl J Med 340 1999 438 447
67. S. Zou, K.A. Dorsey, and E.P. Notari Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing Transfusion 50 2010 1495 1504
68. J.S. Epstein, and J.A. Holmberg Progress in monitoring blood safety Transfusion 50 2010 1408 1412
69. FDA. Guidance for industry: an acceptable circular of information for the use of human blood and blood components. Available at: http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ ucm074940.htm.
70. H.J. Alter, S.L. Stramer, and R.Y. Dodd Emerging infectious diseases that threaten the blood supply Semin Hematol 44 2007 32 41
71. P.M. Ness, D.L. Bourke, and P.C. Walsh A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgery Transfusion 32 1992 226 230
72. C.W. Hogue Jr., L.T. Goodnough, and T.G. Monk Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy Transfusion 38 1998 924 931
73. L.T. Goodnough, and R.E. Marcus Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron Vox Sang 75 1998 128 133
74. L.T. Goodnough, T.H. Price, and S. Rudnick Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy Transfusion 32 1992 441 445
75. FDA safety announcement: information on Erythropoiesis-Stimulating Agents (ESA) epoetin alfa (marketed as Procrit, Epogen) darbepoetin alfa (marketed as Aranesp) February 16, 2010 Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm [accessed on 21.08.12]
76. L.T. Goodnough Transfusion triggers Surgery 142 2007 S67 S70
77. T.J. Littlewood, E. Bajetta, and J.W. Nortier Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
78. J.L. Canon, J. Vansteenkiste, and M. Hedenus Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial Med Oncol 29 2012 2291 2299
79. O. Sowade, H. Warnke, and P. Scigalla Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery Blood 89 1997 411 418
80. O. Sowade, S. Ziemer, and B. Sowade The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery J Lab Clin Med 129 1997 376 383
81. O. Sowade, J. Gross, and B. Sowade Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta J Lab Clin Med 129 1997 97 105
82. M.N. D'Ambra, R.J. Gray, and R. Hillman Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients Ann Thorac Surg 64 1997 1686 1693
83. L.T. Goodnough, G.J. Despotis, and C.A. Parvin Erythropoietin therapy in patients undergoing cardiac operations Ann Thorac Surg 64 1997 1579 1580
84. D.M. Moskowitz, J.J. Klein, and A. Shander Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center Ann Thorac Surg 77 2004 626 634
85. L. Weltert, S. D'Alessandro, and S. Nardella Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study J Thorac Cardiovasc Surg 139 2010 621 626 [discussion 6-7]